◆ 会议时间：2024年9月8-11日
◆ 会议地点：美国 国家海港
◆ 会议简介：
2023年第7届CRI-ENCI国际癌症免疫治疗大会:将科学转化为生存将于2024年9月8-11日在美国马里兰州国家海港举行，会议议题涵盖癌症免疫学和免疫治疗的所有研究领域。该会议于2015年启动，本次会议由癌症研究所（CRI）、欧洲癌症免疫治疗网络(ENCI)联合主办。会议每年举行一次，在美国和欧洲之间轮流举行。通过这种合作，这些组织旨在更有效地传播癌症免疫学和免疫治疗方面最前沿的信息和研究，并为该领域宣所有利益相关者提供交流、学习和沟通的机会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）
CICON 2024
CRI-ENCI Eighth International Cancer Immunotherapy Conference 2024
Translating Science into Survival
Dates: September 8-11, 2024
Venue: GAYLORD NATIONAL RESORT & CONVENTION CENTER, NATIONAL HARBOR, MD, USA
Organized by:
Cancer Research Institute (CRI)
European Network for Cancer Immunotherapy (ENCI)
The Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI) are proud to present the Eighth International Cancer lmmunotherapy Conference.
The program will focus on "Translating Science into Survival," and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates.
摘要征文投稿：
Important Dates
- Abstract Submission Deadline: June 3, 2024
- Abstract Status Notification Date: July 8, 2024
- Withdrawal Deadline: August 1, 2024
SUBMIT YOUR ABSTRACT
Submission
Abstracts may only be submitted through the online abstract submission platform, which will open soon. Only those abstracts that have been reviewed and selected by the Scientific Planning Committee may be presented. Please be sure to carefully check your abstract for content errors, spelling, names, etc. before submitting. The organizers do not proofread or correct spelling, typographical, grammatical, or scientific errors, nor can changes be made once the abstract is submitted. For technical questions or if you have policy related questions, please contact the abstract submission help desk at abstracts@cancerimmunotherapyconference.org.
From the accepted posters, a small number of highly rated abstract authors will also be invited to deliver short oral proffered presentations of their work during the general sessions. All abstracts will be considered. If selected, instructions will be sent to the Submitting Author with the date, time, and format for the presentation.
Notification of Abstract Status
Submitting Author will be notified of acceptance or rejection by email to the address provided by the abstract submitter at the time of submission.
Presentation and Publication
The titles and presenting authors of all regular abstracts scheduled for presentation at CICON24 will be available online prior to the conference. With the exception of abstracts selected for a conference press program (if applicable), all conference abstracts will not be available until several days prior to the start of the conference.
Poster board dimensions will be provided in email correspondence to the Submitting Author. The organizers will provide poster numbers and pushpins.
Conference Registration
Presenting Authors must register for the conference prior to the submission of an abstract and attend the session in which the abstract is scheduled.
Request for Withdrawal
Once an abstract has been submitted, it may be withdrawn only by written request from the Submitting Author. The request may be sent by email to abstracts@cancerimmunotherapyconference.org and must be received by August 1, 2024.
If due to unforeseen circumstances the designated Presenting Author is unavailable to attend the session to present the abstract, the Submitting Author must contact abstracts@cancerimmunotherapyconference.org to designate a co-author to serve as the Presenting Author. If no authors are available to present the abstract, the Submitting Author must withdraw the abstract immediately by emailing abstracts@cancerimmunotherapyconference.org.
Abstract Categories
- Neoadjuvant and Platform Trials
- Multiomic Data Analysis: Searching for Mechanistic Insights
- Tertiary Lymphoid Aggregates as Regulators of Anti-Cancer Immunity
- Immune Health and Inflammation as Precursors to Cancer
- The Role of Myeloid Cells in the Anti-tumor Response
- New Tools, Technologies, and Approaches in Cancer Immunotherapy
- Metabolism: Metabolomic Pathways in the Clinic
- Microbiome --> Diet and Microbiome
- Moving Toward Personalized Therapies: Cellular & Vaccines
- Clinical Trials
- Other
注册费：
The deadline for Early Registration at the reduced early rate is July 15, 2024. Online registration will close on September 7, 2024. On-site registration will be accepted, space permitting.
Group Registration: Register 3 or more participants from the same lab and receive a 5% discount on each registrant. All 3 lab members must be registered at the same time.
Non-member Pre-/Postdoctoral Students or Fellows must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research. Documentation of enrollment must be provided upon registration.
If you are a Patient Advocate registering for this conference, you must send a biography and pamphlet of your organization to info@cancerimmunotherapyconference.org for verification.
Press Registration: Members of the media should contact Dustin Etheridge at detheridge@cancerresearch.org to inquire about registering.
Refund Policy: Requests for refunds must be made in writing to register@cancerimmunotherapyconference.org. There will be a $75 processing fee for cancellations received before August 8, 2024. After August 8, no refunds will be given.
◆ 参会对象：
科学家，临床医生，监管机构，药物开发人员和患者权益倡导者，以及其他相关卫生保健专业人士。
|
